23 NOWE BADANIA KLINICZNE

W dniu 1.08.2019 r. sfinalizowano aktualizację listy badań klinicznych w poszczególnych ankietach ewaluacyjnych, dodając oraz usuwając następujące badania:Atopowe zapalenie skóry:
Dodano:
-CrisaboroleAtD(A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD)
-JADE EXTEND(Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis)
-TezapeAtD(A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis)
-NemoliAtD(Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis)Przewlekła choroba nerek:
Dodano:
-SAPPHIRE(A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia)
-FERUXIDA(A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD))
-VALOR-CKD(Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis)
-PRO2TECT(Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD))
-PRO2TECT.2(Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD))
-KALM-2(CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus)Reumatoidalne zapalenie stawów:
Dodano:
-ABBV105/599(A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib.)
-RA-BRIDGE(A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis)
Usunięto:
*-*FINCH IV(Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis)
-EVO(Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis)Stwardnienie rozsiane:
*Dodano:
-*OfatSM(Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS)
Usunięto:
*-*EVOLVE-MS-2(A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis)Toczeń rumieniowaty układowy:
*Dodano:
-*LTBMS-986165 SLE(Long-Term Safety and Efficacy Study of BMS-986165 in Participants With Systemic Lupus Erythematosus)
-ABBV-105&Upa(A Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus)
*-*VAY736 & CFZ533 SLE(Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients)
-BMS-986165 LupNephr(An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis)
Usunięto:
**-LILAC (**Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus)Wrzodziejące zapalenie jelita grubego:
Dodano:
-ABX464 2b(Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis)
-BMS-986165 UC(Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis (UC))
-RHEA(Efficacy & Safety of TD-1473 in Ulcerative Colitis)
-TD-1473 UC(Efficacy & Safety of TD-1473 in Ulcerative Colitis)
-SHR0302 UC(A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis)
-ST-0529 UC(A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis)
Usunięto:
-AiPSwMtSUC(Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis)
-EtroPedUC(A Phase I Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric Patients With Moderate To Severe Ulcerative Colitis Or Moderate To Severe Crohn's Disease)